



SAFETY DATA SHEET

Revision date: 29-Jan-2015

Version: 2.0

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Azithromycin Film-Coated Tablets (Greenstone LLC)

Trade Name: Not applicable
Chemical Family: Azalide

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Greenstone LLC
100 Route 206 North
Peapack, NJ 07977
800-435-7095

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Signal Word: Not required

Other Hazards

No data available

Australian Hazard Classification (NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Azithromycin dihydrate	117772-70-0	Not Listed	Not Listed	Not Listed	56
Croscarmellose sodium	74811-65-7	Not Listed	Not Listed	Not Listed	*
Starch, pregelatinized	9005-25-8	232-679-6	Not Listed	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	Not Listed	*

SAFETY DATA SHEET

Material Name: Azithromycin Film-Coated Tablets
(Greenstone LLC)
Revision date: 29-Jan-2015

Page 2 of 9

Version: 2.0

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Calcium phosphate dibasic, anhydrous	7757-93-9	231-826-1	Not Listed	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

SAFETY DATA SHEET

Material Name: Azithromycin Film-Coated Tablets
(Greenstone LLC)
Revision date: 29-Jan-2015

Page 3 of 9

Version: 2.0

**Measures for Cleaning /
Collecting:**

Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for
Large Spills:**

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes. Minimize dust generation and accumulation. Use appropriate ventilation. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

SAFETY DATA SHEET

Material Name: Azithromycin Film-Coated Tablets
(Greenstone LLC)
Revision date: 29-Jan-2015

Page 4 of 9

Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Azithromycin dihydrate	
Manufacturer OEL:	500ug/m ³
Calcium phosphate dibasic, anhydrous	
Latvia OEL - TWA	10 mg/m ³
Starch, pregelatinized	
ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	5 mg/m ³
	10 mg/m ³
	4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Magnesium stearate	
ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	5 mg/m ³

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls:

Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

SAFETY DATA SHEET

Material Name: Azithromycin Film-Coated Tablets
(Greenstone LLC)
Revision date: 29-Jan-2015

Page 5 of 9

Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Film-coated tablets	Color:	Pink
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Croscarmellose sodium

No data available

Calcium phosphate dibasic, anhydrous

No data available

Starch, pregelatinized

No data available

Magnesium stearate

No data available

Sodium lauryl sulfate

No data available

Azithromycin dihydrate

Measured 7 Log P 0.67

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

Polymerization: Will not occur

Partition Coefficient 0.65 @ 20°C & pH= 7 (azithromycin)
(n-octanol/water - ELog D):

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

Products:

SAFETY DATA SHEET

Material Name: Azithromycin Film-Coated Tablets
(Greenstone LLC)
Revision date: 29-Jan-2015

Page 6 of 9

Version: 2.0

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Short Term:

Dust may cause irritation if tablets are crushed or broken. Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions.

Known Clinical Effects:

May cause effects similar to those seen in clinical use including transient diarrhea, nausea and abdominal pain.

Acute Toxicity: (Species, Route, End Point, Dose)

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Sodium lauryl sulfate

Rat Oral LD50 1288 mg/kg

Azithromycin dihydrate

Mouse (F) Oral LD50 4000 mg/kg
Mouse (M) Oral LD50 3000mg/kg
Rat Oral LD50 > 2000mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium lauryl sulfate

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild Moderate
Skin Sensitization - GPMT Guinea Pig Negative
Skin Sensitization - LLNA Mouse Negative

Azithromycin dihydrate

Antigenicity- Active anaphylaxis Guinea Pig Negative
Antigenicity- Passive cutaneous anaphylaxis Rabbit Negative
Antigenicity- Passive cutaneous anaphylaxis Mouse Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Azithromycin dihydrate

6 Month(s) Rat Oral 10 mg/kg/day LOEL Liver
6 Month(s) Dog Oral 10 mg/kg/day LOEL Liver
1 Month(s) Rat Intravenous 5 mg/kg/day NOEL Liver
1 Month(s) Dog Intravenous 5 mg/kg/day NOEL Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Azithromycin dihydrate

Reproductive & Fertility Rat Oral 10 mg/kg/day NOEL Fertility
Prenatal & Postnatal Development Mouse Oral 40 mg/kg/day NOEL Not Teratogenic
Prenatal & Postnatal Development Rat Oral 40 mg/kg/day NOEL Not Teratogenic

SAFETY DATA SHEET

Material Name: Azithromycin Film-Coated Tablets
(Greenstone LLC)
Revision date: 29-Jan-2015

Page 7 of 9

Version: 2.0

11. TOXICOLOGICAL INFORMATION

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sodium lauryl sulfate

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Azithromycin dihydrate

Bacterial Mutagenicity (Ames) *Salmonella* Negative

In Vivo Cytogenetics Mouse Lymphoma Negative

In Vitro Cytogenetics Mouse Negative

In Vitro Cytogenetics Human Lymphocytes Negative

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview:

In the environment, the active ingredient in this formulation is expected to mainly reside in the aquatic environment and slowly degrade.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Sodium lauryl sulfate

Oncorhynchus mykiss (Rainbow Trout) LC50 96 Hours 3.6 mg/L

Azithromycin dihydrate

Daphnia magna (Water Flea) OECD EC50 48 Hours 120 mg/L

Hyallela azteca (Freshwater Amphipod) OECD LC50 96 Hours > 120 mg/L

Oncorhynchus mykiss (Rainbow Trout) OECD LC50 96 Hours > 84 mg/L

Green Algae OECD EC50 72 Hours 0.0037 mg/L

Microcystis aeruginosa (Blue-green Alga) OECD ErC50 96 Hours 0.0018 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Azithromycin dihydrate

Aspergillus niger (Fungus) OECD MIC > 1000 mg/L

Trichoderma viride (Fungus) OECD MIC > 1000 mg/L

Clostridium perfringens (Bacterium) OECD MIC 2.0 mg/L

Bacillus subtilis (Bacterium) OECD MIC 2.0 mg/L

Azithromycin dihydrate

Eisenia foetida (Earthworm) TAD NOEC 28 Days 1000 mg/kg

Azithromycin dihydrate

Pimephales promelas (Fathead Minnow) OECD 32 Day(s) NOEC 4.6 mg/L Survival

Ceriodaphnia dubia (Daphnids) OPPTS 7 Day(s) NOEC 0.0044 mg/L Reproduction

Persistence and Degradability:

No data available

SAFETY DATA SHEET

Material Name: Azithromycin Film-Coated Tablets
(Greenstone LLC)
Revision date: 29-Jan-2015

Page 8 of 9

Version: 2.0

Bio-accumulative Potential: No data available
Azithromycin dihydrate
Measured 7 Log P 0.67

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Non-controlled

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Azithromycin dihydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Calcium phosphate dibasic, anhydrous

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-826-1

SAFETY DATA SHEET

Material Name: Azithromycin Film-Coated Tablets
(Greenstone LLC)
Revision date: 29-Jan-2015

Page 9 of 9

Version: 2.0

15. REGULATORY INFORMATION

Croscarmellose sodium

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Starch, pregelatinized

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

Magnesium stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

16. OTHER INFORMATION

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients.

Revision date: 29-Jan-2015

Product Stewardship Hazard Communication

Prepared by: Global Environment, Health, and Safety Operations

It is believed that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time

End of Safety Data Sheet